We are currently upgrading our print fulfillment systems. Print book orders placed between Sept 22 and Oct 9 will be delayed. Delivery of these orders will start on Oct 10, with purchases being fulfilled in the order received. Buy the Print and get eBook immediately for FREE. Use Code BOGO. Or save up to 40% on all orders with code: DELTA. Exclusions apply. Click here for terms and conditions.
»
Biotechnology Annual Review
 
 

Biotechnology Annual Review, 1st Edition

 
Biotechnology Annual Review, 1st Edition,M. Raafat El-Gewely,ISBN9780444517494
 
 
 

  

Elsevier Science

9780444517494

322

286 X 221

Print Book

Hardcover

In Stock

Estimated Delivery Time
USD 315.00
 
 

M. Raafat El-Gewely

Affiliations and Expertise

Department of Biotechnology, Institute of Medical Biology, University of Tromso, Norway

View additional works by M. Raafat El-Gewely

Biotechnology Annual Review, 1st Edition

Foreword - What is Biotechnology Today? (Leroy Hood, The Institute for Systems Biology, Seattle, WA, USA)
  1. Rapid translation system: a novel cell-free way from gene to protein (M. Hoffmann, C. Nemetz).

  2. Protein expression and refolding - a practical guide to getting the most out of inclusion bodies (L.D. Cabrita, S. Bottomley).

  3. Towards a systems biology understanding of human health: interplay between genotype, environment and nutrition.

  4. Public health issues related with the consumption of food obtained from genetically modified organisms (A. Paparini, V. Romano-Spica).

  5. p75 neurotrophin receptor signaling in the nervous system (Y. Hasegawa et al.).

  6. Phage display for epitope determination: a paradigm for identifying receptor-ligand interactions (M.J. Rowley, K. O'Connor, L. Wijeyewickrema).

  7. DNA vaccines and their application against parasites - promise, limitations and potential solutions (P.M. Smooker et al.).

  8. Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge (R. Smalling et al.).

  9. Using the biologic license application or new drug application as a basis for the common technical document (M. Foote).

  10. Guidelines and policies for medical writers in the biotech industry: an update on the controversy (M. Foote).

  11. Radioimmunotherapy of Non-Hodgkin's lymphoma: clinical development of the zevalin regimen (C.P. Theuer et al.).

  12. Biosimulation software is changing research (R.L.X. Ho, L.T. Bartsell).

 
 
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy
FAQ